Pre-market Hot Trades in US Stocks
AgomAb Therapeutics NV, down 11.26% in pre-market trading, has no significant recent news. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Strategy is down 4.80% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 6, Strategy announced its fourth-quarter financial report, showing a net loss widened to $12.619 billion, mainly affected by the decline in Bitcoin prices. The Bitcoin price fell below the company's holding cost, leading to a significant drop in stock price by 17%. Source: MarketWatch
</li>
<li>
On February 6, Strategy's market capitalization fell below the market value of its Bitcoin holdings, raising concerns that the company may be forced to adjust its holding strategy. Analysts pointed out that if mNAV falls below 1, the company may sell Bitcoin. Source: Zhitong Finance
</li>
<li>
On February 7, Bitcoin prices rebounded by about 13%, and Strategy's stock price rose by 26%, recovering the previous day's losses. Analysts believe the company has the capacity to withstand further declines in Bitcoin. Source: TD Cowen Analyst Report. The cryptocurrency market is highly volatile, and risks need to be monitored.
</li>
</ol>
Top Gainers in Pre-market US Stocks
MDJM, up 108.40% in pre-market trading, has no significant recent news. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
CRD.B is up 38.97% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 6, Crawford &amp; Company announced a quarterly dividend of $0.075 per share, with a dividend yield of 2.71%. This news may have boosted investor confidence, driving the stock price up. Source: Business Wire
</li>
<li>
On February 6, Crawford United Corporation completed a merger and revised its corporate charter, which may have sparked positive market expectations for the company's future development, further driving the stock price up. Source: EDGAR
</li>
<li>
On February 5, Crawford &amp; Company’s board approved the quarterly dividend, further solidifying investor confidence in the company's financial stability. Source: Business Wire. The overall industry performance is stable, with significant capital inflow.
</li>
</ol>
CCH is up 25.44% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 6, CCH Holdings stock rose 70.69% in pre-market trading, mainly due to its low float and the stock price being in the low-price range, attracting attention from retail traders. This type of stock is usually susceptible to retail trader influence, leading to significant price fluctuations. The trading volume that day exceeded 44 million shares, far above the three-month average daily trading volume of about 481,000 shares
</li>
<li>
On February 5th, CCH Holdings' stock rose slightly, despite a 25.27% decline in price year-to-date. This volatility may be related to increased market interest in low float stocks.
</li>
<li>
Recently, the volatility of CCH Holdings' stock has increased, possibly due to its low float and market attention on low-priced stocks. A low float increases volatility risk
</li>
</ol>

AGMB

MSTR

AgomAb Therapeutics NV pre-market down 11.26%; Strategy pre-market down 4.80%; MDJM pre-market up 108.40%; Crawford & Company Class B pre-market up 38.97%; CCH pre-market up 25.44%

Pre-market hot trades in US stocks: AgomAb Therapeutics NV pre-market down 11.26%; Strategy pre-market down 4.80%